Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Brain Research
|
December 15, 1994
Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice
L Mucke, E Masliah, W B Johnson, et al.
Frontiers in Immunology
|
March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses
Tony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
ACS Medicinal Chemistry Letters
|
April 25, 2017
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit
Henry W B Johnson, Janet L Anderl, Erin K Bradley, et al.
Oncogene
|
October 18, 2006
Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling
Y F Wong, T H Cheung, K W K Lo, et al.
Journal of Medicinal Chemistry
|
January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists
Mohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Journal of Medicinal Chemistry
|
February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)
Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 16, 2025
Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity
Eric Lowe, Janet L Anderl, David Bade, et al.
Journal of Medicinal Chemistry
|
May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors
James W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
Timothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Brain Research
|
December 15, 1994
Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice
L Mucke, E Masliah, W B Johnson, et al.
Frontiers in Immunology
|
March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses
Tony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
ACS Medicinal Chemistry Letters
|
April 25, 2017
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit
Henry W B Johnson, Janet L Anderl, Erin K Bradley, et al.
Oncogene
|
October 18, 2006
Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling
Y F Wong, T H Cheung, K W K Lo, et al.
Journal of Medicinal Chemistry
|
January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists
Mohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Journal of Medicinal Chemistry
|
February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)
Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 16, 2025
Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity
Eric Lowe, Janet L Anderl, David Bade, et al.
Journal of Medicinal Chemistry
|
May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors
James W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
Timothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.
Page
of 7